Welcome to Vivacelle Bio Inc.

VIVACELLE BIO, Inc. is a developmental stage biotechnology company focused on creating products that utilize nanoparticle technology.  The  Company's first product, VBI-1, is a colloid non-blood volume expander that appears to be two to three times more effective than the standard treatment for hypovolemia and safer in animal studies/experiments.  On February 1, 2019, the FDA granted clearance to initiate our phase IIa clinical trial using VBI-1.  VBI-1, is primarily-designed to treat hypovolemia due to hemorrhagic shock (blood loss).The company is also developing a second product, VBI-S, to treat hypovolemia due to sepsis/septic shock.  This new class of resuscitation fluids is named, VIVACELLE. 

VIVACELLE restores blood pressure, circulating volume and there by increases survival in animal models of hypovolemia.  Hypovolemia, which occurs when there is inadequate fluid volume in the blood vessels, causes the death of over a one million people globally each year.  Causes include  acute blood loss from trauma, surgery, shock, sepsis, severe diarrhea and burns.  When the circulating volume is inadequate to maintain tissue perfusion and oxygenation, cellular injury and death may result.

Rapid volume replacement and re-establishment of normal blood pressure are essential to survival. Unfortunately, the current fluid treatments for hypovolemia, such as non-blood volume expanders (colloids and crystalloids), blood products and blood substitutes have proven impractical and have the potential for significant negative adverse effects.  VBI-1, a suspension of lipid droplets which form nanoparticles represents a new paradigm for use in fluid resuscitation, safely restoring blood vessel volume and reversing the effects of hypovolemia.  In addition, VBI-1 has several promising properties that may address other detrimental events contributing to cell death: 

• Modulates Nitric Oxide (NO), (a potent vasodilator that drops the blood pressure and a precursor to highly toxic mediators)  
• Reduces reperfusion injury 
• Inhibits the inflammatory response 
• Can be loaded with readily released oxygen 
• Increases clearance of endotoxin 
• Metabolizable and naturally-occurring components 
• Provides an energy source